Related Experiment Video
Updated: Jul 29, 2026
07:25
Assessing Murine Resistance Artery Function Using Pressure Myography
Published on: June 7, 2013
Summary
Hydralazine and its acetone condensation product (ACP) are genotoxic, causing mutations. Slow acetylators, who metabolize hydralazine slowly, may face increased health risks from this drug.
Area of Science:
- Pharmacology
- Toxicology
- Genetics
Background:
- Hydralazine is a vasodilator used to treat hypertension.
- Understanding the genotoxicity of hydralazine and its metabolites is crucial for patient safety.
Purpose of the Study:
- To investigate the genotoxic potential of hydralazine and its derivatives.
- To assess the role of metabolic activation in hydralazine-induced genotoxicity.
Main Methods:
- Bacterial mutagenicity assays (Salmonella/microsomal test system).
- Genetic toxicity tests (PolA+/A- system).
- Incubation with rat-liver microsomal fractions to assess metabolic activation.
Main Results:
- Hydralazine and its acetone condensation product (ACP) induced base-pair substitution mutations and genetic toxicity.
- Metabolic activation by rat-liver microsomes did not alter the genotoxicity of hydralazine or ACP.
- Other hydralazine derivatives, including a major metabolite, showed no evidence of genotoxicity.
Conclusions:
- Hydralazine and ACP exhibit direct genotoxic effects.
- Individuals with slow acetylator phenotypes may be at higher risk due to impaired hydralazine metabolism.
Related Concept Videos
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...